Buntanetap tartrate by Annovis Bio for Lewy Body Dementia: Likelihood of Approval
Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase II for Lewy Body Dementia.
Source: pharmaceutical-technology.com
Page 9 - Pharmaceutical Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmaceutical Intelligence Today - Breaking & Trending Today
ST-266 by Noveome Biotherapeutics for Chronic Traumatic Encephalopathy (CTE): Likelihood of Approval
ST-266 is under clinical development by Noveome Biotherapeutics and currently in Phase I for Chronic Traumatic Encephalopathy (CTE).
Source: pharmaceutical-technology.com
Epcoritamab by Genmab for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL).
Source: pharmaceutical-technology.com
DISC-0974 by Disc Medicine for Myeloproliferative Disorders: Likelihood of Approval
DISC-0974 is under clinical development by Disc Medicine and currently in Phase I for Myeloproliferative Disorders.
Source: pharmaceutical-technology.com
Upadacitinib ER by AbbVie for Alopecia Areata: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase III for Alopecia Areata.
Source: pharmaceutical-technology.com